Two out of the three major indices are trading lower today with the Dow Jones Industrial Average ( ^DJI) trading down 37 points (-0.2%) at 16,376 as of Friday, Feb. 19, 2016, 11:55 AM ET. The NYSE advances/declines ratio sits at 1,270 issues advancing vs. 1,648 declining with 149 unchanged.

The Drugs industry currently sits up 0.6% versus the S&P 500, which is down 0.1%. On the negative front, top decliners within the industry include Gilead ( GILD), down 0.9%, Celgene ( CELG), down 0.7%, AbbVie ( ABBV), down 0.6% and Merck ( MRK), down 0.5%. Top gainers within the industry include Biomarin Pharmaceutical ( BMRN), up 3.0%, Bristol-Myers Squibb Company ( BMY), up 1.7%, Alexion Pharmaceuticals ( ALXN), up 0.9%, Regeneron Pharmaceuticals ( REGN), up 0.9% and Novo Nordisk A/S ( NVO), up 0.8%.

TheStreet would like to highlight 3 stocks pushing the industry lower today:

3. AstraZeneca ( AZN) is one of the companies pushing the Drugs industry lower today. As of noon trading, AstraZeneca is down $0.32 (-1.1%) to $29.38 on average volume. Thus far, 2.5 million shares of AstraZeneca exchanged hands as compared to its average daily volume of 4.3 million shares. The stock has ranged in price between $29.17-$29.40 after having opened the day at $29.18 as compared to the previous trading day's close of $29.70.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

AstraZeneca PLC engages in the discovery, development, and commercialization of prescription medicines for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection, and neuroscience diseases worldwide. AstraZeneca has a market cap of $76.0 billion and is part of the health care sector. Shares are down 12.5% year-to-date as of the close of trading on Thursday. Currently there is 1 analyst that rates AstraZeneca a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates AstraZeneca as a hold. The company's strengths can be seen in multiple areas, such as its impressive record of earnings per share growth, compelling growth in net income and notable return on equity. However, as a counter to these strengths, we also find weaknesses including weak operating cash flow and a generally disappointing performance in the stock itself. Get the full AstraZeneca Ratings Report now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

2. As of noon trading, Perrigo ( PRGO) is down $3.37 (-2.6%) to $127.03 on heavy volume. Thus far, 1.6 million shares of Perrigo exchanged hands as compared to its average daily volume of 1.6 million shares. The stock has ranged in price between $126.25-$129.87 after having opened the day at $129.16 as compared to the previous trading day's close of $130.40.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Perrigo Company plc, through its subsidiaries, develops, manufactures, and markets over-the-counter (OTC) consumer goods and pharmaceutical products worldwide. Perrigo has a market cap of $21.3 billion and is part of the health care sector. Shares are down 9.9% year-to-date as of the close of trading on Thursday. Currently there are 8 analysts that rate Perrigo a buy, no analysts rate it a sell, and 7 rate it a hold.

TheStreet Ratings rates Perrigo as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including a decline in the stock price during the past year, disappointing return on equity and weak operating cash flow. Get the full Perrigo Ratings Report now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

1. As of noon trading, Valeant Pharmaceuticals International ( VRX) is down $6.28 (-6.7%) to $87.83 on average volume. Thus far, 5.3 million shares of Valeant Pharmaceuticals International exchanged hands as compared to its average daily volume of 8.4 million shares. The stock has ranged in price between $86.61-$92.42 after having opened the day at $90.48 as compared to the previous trading day's close of $94.11.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Valeant Pharmaceuticals International, Inc. develops, manufactures, and markets pharmaceuticals, over-the-counter products, and medical devices worldwide. Valeant Pharmaceuticals International has a market cap of $32.5 billion and is part of the health care sector. Shares are down 7.4% year-to-date as of the close of trading on Thursday. Currently there are 9 analysts that rate Valeant Pharmaceuticals International a buy, no analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates Valeant Pharmaceuticals International as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, good cash flow from operations and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including a generally disappointing performance in the stock itself, unimpressive growth in net income and generally higher debt management risk. Get the full Valeant Pharmaceuticals International Ratings Report now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).